Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Folashade Otegbeye

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Nature Communications|December 11, 2021
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patientsMichael Maschan, Paolo F Caimi, Jane Reese-Koc, et al.
Transplantation and Cellular Therapy|April 14, 2022
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell TransplantationNaveed Ali, Ashish Arunkumar Sharma, Ana Carolina Pires de Rezende, et al.
Eclinicalmedicine|March 21, 2025
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialArmin Ghobadi, Paolo F Caimi, Jane S Reese, et al.
Blood Advances|December 3, 2024
Development and validation of predictive models of early immune effector cell-associated hematotoxicityEmily C Liang, Jennifer J Huang, Andrew J Portuguese, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Nature Communications|December 11, 2021
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patientsMichael Maschan, Paolo F Caimi, Jane Reese-Koc, et al.
Transplantation and Cellular Therapy|April 14, 2022
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell TransplantationNaveed Ali, Ashish Arunkumar Sharma, Ana Carolina Pires de Rezende, et al.
Eclinicalmedicine|March 21, 2025
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialArmin Ghobadi, Paolo F Caimi, Jane S Reese, et al.
Blood Advances|December 3, 2024
Development and validation of predictive models of early immune effector cell-associated hematotoxicityEmily C Liang, Jennifer J Huang, Andrew J Portuguese, et al.
Pageof 4